Anterogen.Co (065660) Fundamentals 2026 — Revenue Analysis | SniperIQ
Anterogen.Co (065660) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩164.2B, trading at ₩16410.00 on the KOE. This SniperIQ fundamentals page covers Anterogen.Co's valuation, profitability (net margin -19.3%), revenue (₩7.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Anterogen.Co's market cap?
Anterogen.Co (065660) has a market capitalization of approximately ₩164.2B, trading at ₩16410.00 on the KOE. Market cap moves with the live share price.
What is Anterogen.Co's P/E ratio?
Anterogen.Co's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Anterogen.Co?
Anterogen.Co runs a net profit margin of -19.3%, a gross margin of 31.4%, and an operating margin of -30.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Anterogen.Co generate?
Anterogen.Co reported revenue of ₩7.5B for fiscal year 2025, with net income of -₩1.1B and earnings per share (EPS) of -110.37. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Anterogen.Co pay a dividend?
Anterogen.Co does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Anterogen.Co financially healthy?
Anterogen.Co carries a debt-to-equity ratio of 0.00x and a current ratio of 63.40x, with a market beta of 0.02. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Anterogen.Co a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Anterogen.Co (065660) the key facts are: market cap ₩164.2B, revenue ₩7.5B, 52-week range 13500-61800. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Anterogen.Co's full fundamentals live
Get Anterogen.Co's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.